Elite in Waldenstrom Macroglobulinemia

Pierre Morel

Amiens, FR 
Elite in Waldenstrom Macroglobulinemia
Amiens, FR 
OverviewLocationsClinical Research

Overview

Pierre Morel practices in Amiens, France. Mr. Morel is rated as an Elite expert by MediFind in the treatment of Waldenstrom Macroglobulinemia. His top areas of expertise are Waldenstrom Macroglobulinemia, Febrile Neutropenia, Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, and Bone Marrow Transplant.

His clinical research consists of co-authoring 67 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 35 articles in the study of Waldenstrom Macroglobulinemia.

Gender
Male

Locations

Amiens, France
Other Locations
Limoges, France
Calais, France
Salouel, France
France
Lens, France
Clermont-ferrand, France
Lille, France
Toulouse, France
Bron, 69500, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)
A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)
Enrollment Status: Completed
Publish Date: October 04, 2022
Intervention Type: Drug
Study Phase: Phase 2
Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association
Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association
Enrollment Status: Completed
Publish Date: April 13, 2021
Intervention Type: Drug
Study Drugs: Lenalidomide, Rituximab
Study Phase: Phase 3
Prospective Multicentre Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® by Intrathecal Injection in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis
Prospective Multicentre Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® by Intrathecal Injection in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis
Enrollment Status: Completed
Publish Date: August 23, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

67 Total Publications

Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.
Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.
Journal: Leukemia
Published: July 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Morel's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile